Search Results - "Warburton, Lydia"

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients by McEvoy, Ashleigh C, Warburton, Lydia, Al-Ogaili, Zeyad, Celliers, Liesl, Calapre, Leslie, Pereira, Michelle R, Khattak, Muhammad A, Meniawy, Tarek M, Millward, Michael, Ziman, Melanie, Gray, Elin S

“…Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always…”
Get full text

Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients by Warburton, Lydia, Reid, Anna, Amanuel, Benhur, Calapre, Leslie, Millward, Michael, Gray, Elin

“…Immune checkpoint inhibition (ICI) has led to unprecedented outcomes for melanoma patients but is associated with toxicity. ICI resumption after high grade…”
Get full text

Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report by Calapre, Leslie, Warburton, Lydia, Millward, Michael, Gray, Elin S

“…Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. The presence…”
Get full text

Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma by Calapre, Leslie, Giardina, Tindaro, Robinson, Cleo, Reid, Anna L., Al‐Ogaili, Zeyad, Pereira, Michelle R., McEvoy, Ashleigh C., Warburton, Lydia, Hayward, Nicholas K., Khattak, Muhammad A., Meniawy, Tarek M., Millward, Michael, Amanuel, Benhur, Ziman, Melanie, Gray, Elin S.

“…Circulating tumor DNA (ctDNA) may serve as a surrogate to tissue biopsy for noninvasive identification of mutations across multiple genetic loci and for…”
Get full text

First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study by Brown, Lauren Julia, Khou, Victor, Brown, Chris, Alexander, Marliese, Jayamanne, Dasantha, Wei, Joe, Gray, Lauren, Chan, Wei Yen, Smith, Samuel, Harden, Susan, Mersiades, Antony, Warburton, Lydia, Itchins, Malinda, Lee, Jenny H, Pavlakis, Nick, Clarke, Stephen J, Boyer, Michael, Nagrial, Adnan, Hau, Eric, Pires da Silva, Ines, Kao, Steven, Kong, Benjamin Y

“…Brain metastases commonly occur in patients with non-small cell lung cancer (NSCLC). Standard first-line treatment for NSCLC, without an EGFR, ALK or ROS1…”
Get full text

Associations of Physical Activity and Exercise with Health-related Outcomes in Patients with Melanoma During and After Treatment: A Systematic Review by Crosby, Brendan J., Lopez, Pedro, Galvão, Daniel A., Newton, Robert U., Taaffe, Dennis R., Meniawy, Tarek M., Warburton, Lydia, Khattak, Muhammad A., Gray, Elin S., Singh, Favil

“…Purpose: Although exercise medicine is recommended to counter treatment-related side-effects and improve health-related outcomes of patients affected by…”
Get full text

LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC by Alexander, Marliese, Wei, Joe, Parakh, Sagun, John, Thomas, Kao, Steven, Nagrial, Adnan, Bowyer, Samantha, Warburton, Lydia, Moore, Melissa, Hughes, Brett G.M., Clay, Timothy D., Pavlakis, Nick, Solomon, Benjamin J., Itchins, Malinda

“…Over the past decade, ALK tyrosine kinase inhibitors have delivered unprecedented survival for individuals with ALK-positive (ALK+) lung cancers. Real-world…”
Get full text

Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer by Calvo, Emiliano, Spira, Alexander, Miguel, María de, Kondo, Shunsuke, Gazzah, Anas, Millward, Michael, Prenen, Hans, Rottey, Sylvie, Warburton, Lydia, Alanko, Tuomo, Cassier, Philippe A., Yoh, Kiyotaka, Italiano, Antoine, Moreno, Victor, Peltola, Katriina, Seto, Takashi, Toyozawa, Ryo, Afar, Daniel E., Englert, Stefan, Komarnitsky, Philip, Lambert, Stacie, Parikh, Apurvasena, Vosganian, Gregory, Gao, Bo

“…•Budigalimab (formerly ABBV-181) is a humanized, recombinant mAb targeting PD-1.•Rova-T is a delta-like protein 3-targeted antibody-drug conjugate.•Phase 1…”
Get full text

Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma by Calapre, Leslie, Warburton, Lydia, Millward, Michael, Ziman, Mel, Gray, Elin S.

“…Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. In melanoma,…”
Get full text

Extracellular vesicles as a liquid biopsy for melanoma: Are we there yet? by Medhin, Lidia B., Beasley, Aaron B., Warburton, Lydia, Amanuel, Benhur, Gray, Elin S.

“…Melanoma is the most aggressive form of skin cancer owing to its high propensity to metastasise in distant organs and develop resistance to treatment. The…”
Get full text

Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression by Marsavela, Gabriela, McEvoy, Ashleigh C., Pereira, Michelle R., Reid, Anna L., Al-Ogaili, Zeyad, Warburton, Lydia, Khattak, Muhammad A., Abed, Afaf, Meniawy, Tarek M., Millward, Michael, Ziman, Melanie R., Calapre, Leslie, Gray, Elin S.

“…Background The validity of circulating tumour DNA (ctDNA) as an indicator of disease progression compared to medical imaging in patients with metastatic…”
Get full text

Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy by Marsavela, Gabriela, Lee, Jenny, Calapre, Leslie, Wong, Stephen Q, Pereira, Michelle R, McEvoy, Ashleigh C, Reid, Anna L, Robinson, Cleo, Warburton, Lydia, Abed, Afaf, Khattak, Muhammad A, Meniawy, Tarek M, Dawson, Sarah-Jane, Sandhu, Shahneen, Carlino, Matteo S, Menzies, Alexander M, Scolyer, Richard A, Long, Georgina V, Amanuel, Benhur, Millward, Michael, Ziman, Melanie R, Rizos, Helen, Gray, Elin S

“…We evaluated the predictive value of pretreatment ctDNA to inform therapeutic outcomes in patients with metastatic melanoma relative to type and line of…”
Get full text

Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma by Grover, Piyush, Li, Isabel, Kuijpers, Anke, Kreidieh, Firas Y., Williamson, Andrew, Amaral, Teresa Maria Santos, Dimitriou, Florentia, Placzke, Joanna, Olino, Kelly, Vitale, Maria Grazia, Saiag, Philippe, Gutzmer, Ralf, Allayous, Clara, Olofsson Bagge, Roger, Asher, Nethanel, Meniawy, Tarek, Lawless, Aleigha, Warburton, Lydia, Menzies, Alexander M., Long, Georgina V.

“…9518 Background: Pts with resected AJCC v8 stage IIIA melanoma have been under-represented in clinical trials of adjuvant drug therapy. The benefit of adjuvant…”
Get full text

Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT) by Fantoni, Andrew, Warburton, Lydia, Solomon, Benjamin, Alexander, Marliese, Maddula, Meghana, Brown, Lauren Julia, da Silva, Ines Pires, Nagrial, Adnan, Abu Al-Hial, Farah, Itchins, Malinda, Pavlakis, Nick, Bowyer, Samantha

“…•We present real world outcomes of a multi-site Australian cohort of patients with metastatic NSCLC who completed two years of first-line…”
Get full text

Unresectable cardiac metastasis from melanoma responds well to combination immunotherapy-a case report by Oh, Ek Leone, Dias, Peter, Al-Ogaili, Zeyad, Otto, Jacobus, Warburton, Lydia

“…Melanoma can metastasize to distal organs including the heart although presentation with a symptomatic cardiac metastasis is rare. The optimal management…”
Get full text

Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma by Goodman, Rachel S., Di Guardo, Lorenza, Maurichi, Andrea, Kirwin, Brendan, Khattak, Adnan, Vanella, Vito, Lee, Joanna, Lawless, Aleigha, Czapla, Juliane, Spagnoletti, Andrea, Ambrosini, Margherita, Livingstone, Elisabeth, Long, Georgina V., Sullivan, Ryan J., Carlino, Matteo S., Atkinson, Victoria, Trojanello, Claudia, Ascierto, Paolo A., Schadendorf, Dirk, Warburton, Lydia, Menzies, Alexander M., Santinami, Mario, Johnson, Douglas B.

“…Recent studies have shown that approximately 20% of patients have 4–5 year progression free survival (PFS) on BRAF/MEK inhibitors. The long-term safety and…”
Get full text

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes by Lee, Joanna, Ahmed, Tasnia, Maurichi, Andrea, Di Guardo, Lorenza, Stagno, Anna M., Warburton, Lydia, Taylor, Amelia. M., Livingstone, Elisabeth, Rehman, Saba, Khattak, Adnan, Kahler, Katharina C., Vanella, Vito, Atkinson, Victoria, Millward, Michael, Schadendorf, Dirk, Johnson, Douglas B., Ascierto, Paolo A., Hauschild, Axel, Lo, Serigne N., Long, Georgina V., Menzies, Alexander M., Carlino, Matteo S.

“…BRAF mutant melanoma treated with BRAF ± MEK inhibitor (targeted therapy) has a high response rate; however, most patients progress (PD). Some patients have…”
Get full text

Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression by Warburton, Lydia, Calapre, Leslie, Pereira, Michelle R., Reid, Anna, Robinson, Cleo, Amanuel, Benhur, Ziman, Mel, Millward, Michael, Gray, Elin

“…Immunotherapy is an important and established treatment option for patients with advanced melanoma. Initial anti-PD1 trials arbitrarily defined a two-year…”
Get full text

Relapse after cessation of PD-1 based therapy for complete responders in metastatic melanoma by Nguyen, Khang, Mason, Robert, Ladwa, Rahul, Warburton, Lydia, Millward, Michael, Haydon, Andrew Mark, Carlino, Matteo S., Smith, Jessica Louise, Atkinson, Victoria

“…Abstract only…”
Get full text

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma by Italiano, Antoine, Cassier, Philippe A., Lin, Chia-Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her-Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory, Moreno, Victor

“…Background Budigalimab is a humanized, recombinant immunoglobulin G1 monoclonal antibody targeting programmed cell death protein 1 (PD-1). We present the…”
Get full text